Medtech startup Osteopore leads the way for regenerative solutions скачать в хорошем качестве

Medtech startup Osteopore leads the way for regenerative solutions

Listed on the Australian Securities Exchange, Osteopore is a medtech startup made possible through research conducted by the National University of Singapore, National University Hospital and Temasek Polytechnic. To date, the company is the global leader in regenerative solutions and its technology boasts 50,000 successful treatments using patients’ cells and growth factors. In collaboration with clinicians and researchers, Osteopore produces medical implants to meet the needs of both tissue and bone reconstruction as well as restoration. Its bioresorbable implant is the first of its kind to be successfully developed and commercialized for surgical use and is presently used by surgeons across Asia, Europe, Australia and the Americas. In an insightful conversation with Mark Leong, Chairman of Osteopore & Dr Lim Jing, COO & CTO of Osteopore, we discover that the future of healthcare in rebuilding human tissues is already here. Both gentlemen spoke about how the company’s regenerative medicine and tissue engineering technology has benefited patients across the globe, including its plans to further leverage technology to improve patient outcomes and enhance more lives.